Home / Resources / Beyond GLP‑1s: Mapping the Next Generation of Obesity Therapeutics
ON-DEMAND WEBINAR | MAY 29, 2026

Beyond GLP‑1s: Mapping the Next Generation of Obesity Therapeutics

The obesity drug market has expanded rapidly over the past few years, but the next phase of growth will extend well beyond GLP-1s.

In this Scrip-led webinar, our expert journalists examine the evolving obesity landscape, from emerging mechanisms of action and pipeline momentum to market forecasts, deal activity and untapped commercial opportunity. Drawing on intelligence from Evaluate Pharma and Biomedtracker, this session provides essential context for commercial, BD and portfolio decision‑makers navigating what comes next.

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.
What You'll Learn
  • Where innovation is heading beyond GLP‑1s –and which mechanisms show the most promise
  • Key obesity pipeline trends, upcoming catalysts and development focus areas
  • Market forecasts, pricing dynamics and country‑specific opportunities
  • What recent deal activity reveals about future commercial strategy
Meet Our Speakers
Headshot of Aakash Babu.
Aakash Babu
Managing Editor
Pink Sheet, Scrip
Headshot of Joseph Haas.
Joseph Haas (進行役)
Senior Writer, US
Scrip誌 アメリカ担当局員
Headshot of Andrew McConaghie.
Andrew McConaghie
Senior Writer, UK
Scrip誌 イギリス担当局員
Headshot of Xu Hu.
Xu Hu
Senior Reporter, China
Scrip誌 中国担当局員
Aakash Babu
Managing Editor
 Pink Sheet, Scrip
Aakash Babu has covered the pharmaceutical sector since 2018, starting his career at Reuters, where he specialised in tackling company news. Just before joining the Citeline team, he worked as a healthcare analyst at the Economist Group, focusing on disease trends, drug development, regulatory changes and pharmaceutical pricing. He has a master’s in economics and a post-graduate specialisation in business journalism from Asian College of Journalism-Bloomberg. He was a key member of the team that covered the initial breakthroughs in COVID-19 vaccine research during his time at Reuters. He also has experience in forecasting regulatory trends, drug approvals and pharmaceutical sales. Outside of work he enjoys traveling, writing and watching football.
Joseph Haas (進行役)
Senior Writer, US
 Scrip誌 アメリカ担当局員
2007年以降、幅広いバイオ医薬品関連のニュースを取材し、Scrip、In Vivo、Pink Sheetなどサイトラインが保有するメディアに寄稿。専門分野は、事業開発、商業戦略、肝疾患および感染症。
Andrew McConaghie
Senior Writer, UK
 Scrip誌 イギリス担当局員
バイオ医薬品業界におけるR&Dや商業面の幅広いテーマを執筆しています。新興バイオテック企業から、COVID-19ワクチン、がん治療、細胞・遺伝子治療まで、多岐にわたる分野をカバーしています。
Xu Hu
Senior Reporter, China
 Scrip誌 中国担当局員
過去にはメディカルライターとして、グローバル製薬企業向けに幅広い治療領域の臨床試験データに基づく出版物を執筆してきた経験あり。オランダ・フローニンゲン大学で医薬科学の修士号を取得、アムステルダム自由大学で生物医学科学の博士号を取得。中国語と英語のバイリンガル。